Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd (NY: CANF )

1.840 USD +0.040 (+2.22%)
Official Closing Price Updated: 7:59 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 377,500
Open 1.850
Bid (Size) 1.750 (1)
Ask (Size) 1.860 (5)
Prev. Close 1.800
Today's Range 1.690 - 1.860
52wk Range 1.150 - 2.980
Shares Outstanding 19,981,145
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol
Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol 
From Business Wire News Releases
New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today... 
From Business Wire News Releases

Performance

YTD
+1.66%
+1.66%
1 Month
-10.68%
-10.68%
3 Month
-1.08%
-1.08%
6 Month
+8.24%
+8.24%
1 Year
+10.18%
+10.18%

More News

Read More
New Penny Stocks For Your February 2021 Watch List
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies
From Business Wire News Releases
Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH”
From Business Wire News Releases
Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers
From Business Wire News Releases
Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs
From Business Wire News Releases
Can-Fite Reports on Progress With Its Namodenoson NASH Program
From Business Wire News Releases
Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows
Tags Market News Acute Liver Failure Penny Stocks
From Benzinga
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
From PR Newswire
Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.